Search Site
  • 0
    My Cart

    Click Here to Find How Many Items You Have Added:)

    image loader

    Adding item(s) to cart......

Home >> Signaling Pathways >> Tyrosine Kinase >> Src

Src

Src (proto-oncogene tyrosine-protein kinase) is a non-receptor protein tyrosine kinase family including 9 members and promotes survival, angiogenesis, proliferation and invasion pathways.

Products for  Src

  1. Cat.No. Product Name Information
  2. GC38006 β-Hydroxyisovalerylshikonin Beta-hydroxyisovalerylshikonin is a natural product isolated from Lithospermium radix, acts as a potent inhibitor of protein tyrosine kinases (PTK), with IC50s of 0.7μM and 1μM for EGFR and v-Src receptor, respectively. Beta-hydroxyisovalerylshikonin is effective against a wide variety of tumor cell lines, and most efficiently induces cell-death in NCI-H522 and DMS114 cells. β-Hydroxyisovalerylshikonin Chemical Structure
  3. GC12172 1-Naphthyl PP1

    1NaphthylPP1, PP1 Analog

     Src family kinases inhibitor 1-Naphthyl PP1 Chemical Structure
  4. GC34119 1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) 1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) (1-NA-PP 1 hydrochloride) is a selective inhibitor of src family kinases. 1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) inhibits v-Src and c-Fyn, c-Abl, CDK2 and CAMK II with IC50s of 1.0, 0.6, 0.6, 18 and 22 μM, respectively. 1-Naphthyl PP1 hydrochloride (1-NA-PP 1 hydrochloride) Chemical Structure
  5. GC11696 1-NM-PP1

    PP1 Analog II

     Pp60c-src inhibitor 1-NM-PP1 Chemical Structure
  6. GC32992 7-Hydroxy-4-chromone (7-Hydroxychromone) 7-Hydroxychromone is a Src kinase inhibitor with an IC50 of <300 μM. 7-Hydroxy-4-chromone (7-Hydroxychromone) Chemical Structure
  7. GC42616 7-oxo Staurosporine

    BMY 41950, RK-1409

    7-oxo Staurosporine is an antibiotic originally isolated from S.

     7-oxo Staurosporine Chemical Structure
  8. GC35209 A 419259

    RK-20449

     An inhibitor of Src family kinases A 419259 Chemical Structure
  9. GC17789 A 419259 trihydrochloride

    RK-20449

     LCK inhibitor, orally available A 419259 trihydrochloride Chemical Structure
  10. GC35213 A-770041 A-770041 is a selective and orally active Src-family Lck inhibitor. A-770041 Chemical Structure
  11. GC32797 AD80 AD80, a multikinase inhibitor, inhibits RET, RAF,SRCand S6K, with greatly reduced mTOR activity. AD80 Chemical Structure
  12. GC17669 AMG-47A destabilizer of the KRAS oncoprotein AMG-47A Chemical Structure
  13. GC14292 Apatinib Mesylate

    YN968D1

     Apatinib Mesylate blocks the downstream signal transduction of VEGF pathway to inhibit neovascularization. Apatinib Mesylate Chemical Structure
  14. GC32875 AZM475271 (M475271)

    M475271

     AZM475271 (M475271) is a potent and selective Src kinase inhibitor with IC50 of 5 nM; no inhibitory activity on Flt3, KDR, Tie-2. AZM475271 (M475271) Chemical Structure
  15. GC46924 BIBF 1120-13C-d3

    Nintedanib-13C-d3

     A neuropeptide with diverse biological activities BIBF 1120-13C-d3 Chemical Structure
  16. GC13343 Bosutinib (SKI-606)

    SKI 606

     Bosutinib (SKI-606) is an oral Src/Abl tyrosine kinase inhibito with IC50 of 1.2 nM and 1 nM, respectively. Bosutinib (SKI-606) Chemical Structure
  17. GC68796 Bosutinib hydrate

    SKI-606 hydrate

    Bosutinib (hydrate) is an orally available Src/Abl tyrosine kinase inhibitor with IC50 values of 1.2 nM and 1 nM, respectively.

     Bosutinib hydrate Chemical Structure
  18. GC40080 Bosutinib-d8

    SKI-606 D8

     Bosutinib-d8 is intended for use as an internal standard for the quantification of bosutinib by GC- or LC-MS. Bosutinib-d8 Chemical Structure
  19. GC71346 BT424 BT424 is a specific HCK inhibitor. BT424 Chemical Structure
  20. GC50024 Caffeic acid-pYEEIE Phosphopeptide ligand for src SH2 domain Caffeic acid-pYEEIE Chemical Structure
  21. GC64564 Caffeic acid-pYEEIE TFA Caffeic acid-pYEEIE TFA, a non-phosphopeptide inhibitor, exhibits potent binding affinity for the GST-Lck-SH2 domain. Caffeic acid-pYEEIE TFA Chemical Structure
  22. GC49433 Capsiate A capsaicin analog with diverse biological activities Capsiate Chemical Structure
  23. GC40054 CCT241161 CCT241161 is a multi-kinase inhibitor that inhibits B-RAF, B-RAFV600E, C-RAF, Src, and LCK (IC50s = 252, 15, 6, 15, and 3 nM, respectively). CCT241161 Chemical Structure
  24. GC18438 CGP 77675 CGP 77675 is an inhibitor of Src family kinases (SFKs) that blocks the phosphorylation of peptide substrates and autophosphorylation of purified c-Src (IC50s = 5-20 and 40 nM, respectively). CGP 77675 Chemical Structure
  25. GC48992 CGP 77675 (hydrate) An inhibitor of Src family kinases CGP 77675 (hydrate) Chemical Structure
  26. GC64961 CSF1R-IN-2

    CSF1R-IN-2, CSF1R Inhibitor 2, Elzovantinib

     CSF1R-IN-2 (compound 5) is an oral-active inhibitor of SRC, MET and c-FMS, with IC50 values of 0.12 nM, 0.14 nM and 0.76 nM for SRC, MET and c-FMS respectively. CSF1R-IN-2 Chemical Structure
  27. GC15211 Damnacanthal p56lck tyrosine kinase inhibitor Damnacanthal Chemical Structure
  28. GC74027 DAS-5-oCRBN DAS-5-oCRBN is a selective and potent PROTAC degrader of c-Src kinase. DAS-5-oCRBN Chemical Structure
  29. GC15568 Dasatinib (BMS-354825)

    BMS 354825, Sprycel

     An inhibitor of Abl and Src Dasatinib (BMS-354825) Chemical Structure
  30. GC35812 Dasatinib hydrochloride A potent and dual AblWT/Src inhibitor Dasatinib hydrochloride Chemical Structure
  31. GC45687 Dasatinib N-oxide A major metabolite of dasatinib Dasatinib N-oxide Chemical Structure
  32. GC14007 DCC-2036 (Rebastinib)

    DCC-2036

     DCC-2036 (Rebastinib) (DCC-2036) is an orally active, non-ATP-competitiveBcr-Abl inhibitor for Abl1WT and Abl1T315I with IC50s of 0.8 nM and 4 nM, respectively. DCC-2036 (Rebastinib) also inhibits SRC, KDR, FLT3, and Tie-2, and has low activity to seen towards c-Kit. DCC-2036 (Rebastinib) Chemical Structure
  33. GC62107 DGY-06-116 DGY-06-116 is an irreversible covalent, selective Src inhibitor with an IC50 of 3nM. DGY-06-116 inhibits FGFR1 with an IC50 of 8340 nM. DGY-06-116 Chemical Structure
  34. GC32825 eCF506 An inhibitor of Src kinases eCF506 Chemical Structure
  35. GC16519 ENMD-2076 A multi-kinase inhibitor ENMD-2076 Chemical Structure
  36. GC12145 ENMD-2076 L-(+)-Tartaric acid ENMD-2076 L-(+)-Tartaric acid Chemical Structure
  37. GC63390 EPQpYEEIPIYL EPQpYEEIPIYL, a phosphopeptide, is a Src homology 2 (SH2) domain ligand. EPQpYEEIPIYL activates Src family members (e.g. Lck, Hck, Fyn) by binding to SH2 domains. EPQpYEEIPIYL Chemical Structure
  38. GC12958 ER 27319 maleate Selective inhibitor of Syk kinase ER 27319 maleate Chemical Structure
  39. GC70548 Fenlean Fenlean, a natural squamosamide derivative, is a Src tyrosine kinase inhibitor. Fenlean Chemical Structure
  40. GC14807 Fingolimod (FTY720) HCl

    Gilenia; FTY 720; FTY-720

    Fingolimod (FTY720), an immunosuppressant agent, usually used in the treatment of multiple sclerosis, also has anticancer actions and can act as an HDACi (Histone deacetylase inhibitors)[1].

     Fingolimod (FTY720) HCl Chemical Structure
  41. GC50429 GSK 143 Syk inhibitor GSK 143 Chemical Structure
  42. GC71250 GW297361 GW297361 is an oxindole CDK inhibitor that elicits a Pho85-selective response in cells. GW297361 Chemical Structure
  43. GC15000 Herbimycin A

    Antibiotic TAN 420F, NSC 305978

     antibiotic,Src family kinase inhibitor Herbimycin A Chemical Structure
  44. GC65134 HIV-IN-6 HIV-IN-6 is a HIV-Ⅰ viral replication inhibitor by targeting Src family kinases (SFK) that interact with Nef protein of the virus, such as Hck. HIV-IN-6 Chemical Structure
  45. GC73012 HPK1-IN-2 dihydrochloride HPK1-IN-2 didrochloride is a potent and orally active hematopoietic progenitor kinase-1 (HPK1) inhibitor (IC50<0.05 µΜ) with antitumor activity. HPK1-IN-2 dihydrochloride Chemical Structure
  46. GC63606 iHCK-37

    ASN05260065

     iHCK-37 (ASN05260065) is a potent and specific Hck inhibitor with a Ki value of 0.22 μM. iHCK-37 Chemical Structure
  47. GC70499 JNJ-49095397 JNJ-49095397 (RV568) is an inhaled narrow-spectrum kinase inhibitor (NSKI) against both the α and γ isoforms of p38 MAPK. JNJ-49095397 Chemical Structure
  48. GC17638 KB SRC 4 KB SRC 4 is a potent, and highly selective c-Src inhibitor, with a Ki of 44 nM and a Kd of 86 nM, and shows no inhibition on c-Abl up to 125 μM; KB SRC 4 has antitumor activity. KB SRC 4 Chemical Structure
  49. GC73775 KIN-8194 KIN-8194 is an orally active dual inhibitor of HCK and BTK, with IC50 values of 0.915 and <0.495 nM, respectively. KIN-8194 Chemical Structure
  50. GC10523 KX1-004 Pp60c-src inhibitor KX1-004 Chemical Structure
  51. GC72824 KX2-361

    KX-02

     KX2-361 (KX-02) is a Src-kinase and tubulin polymerization inhibitor. KX2-361 Chemical Structure
  52. GC14288 KX2-391

    KX 01, Tirbanibulin

     KX2-391 (KX2-391) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. KX2-391 Chemical Structure
  53. GC10222 KX2-391 dihydrochloride A Src kinase inhibitor KX2-391 dihydrochloride Chemical Structure
  54. GC70315 LCB 03-0110 LCB 03-0110, a thienopyridine derivative, is a potent pan-discoidin domain receptor/c-Src family tyrosine kinase inhibitor. LCB 03-0110 Chemical Structure
  55. GC13117 Lck Inhibitor

    Lymphocyte-specific Protein Tyrosine Kinase, RK-24466

     A selective inhibitor of lymphocyte-specific protein tyrosine kinase Lck Inhibitor Chemical Structure
  56. GC36430 Lck inhibitor 2 Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively Lck inhibitor 2 Chemical Structure
  57. GC13410 Masitinib (AB1010)

    AB-1010, Masican, Masiviera

     Masitinib (AB1010) (AB1010) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib (AB1010) (AB1010) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib (AB1010) Chemical Structure
  58. GC36546 Masitinib mesylate Masitinib mesylate (AB-1010 mesylate) is a potent, orally bioavailable, and selective inhibitor of c-Kit (IC50=200 nM for human recombinant c-Kit). It also inhibits PDGFRα/β (IC50s=540/800 nM), Lyn (IC50= 510 nM for LynB), Lck, and, to a lesser extent, FGFR3 and FAK. Masitinib mesylate (AB-1010 mesylate) has anti-proliferative, pro-apoptotic activity and low toxicity. Masitinib mesylate Chemical Structure
  59. GC10775 MLR 1023

    CP 26,154, NSC 314335

     MLR 1023 is a potent and selective allosteric activator of Lyn kinase with an EC50 of 63 nM. MLR 1023 Chemical Structure
  60. GC10048 MNS

    3,4Methylenedioxyβnitrostyrene, NSC 10120, NSC 105303, NSC 170724, Syk Inhibitor III

     Inhibitor of Src/Syk tyrosine kinases MNS Chemical Structure
  61. GC11526 N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide Phosphopeptide for binding to the src SH2 domain N-Acetyl-O-phosphono-Tyr-Glu Dipentylamide Chemical Structure
  62. GC12746 N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu Phosphopeptide ligand for the src SH2 domain N-Acetyl-O-phosphono-Tyr-Glu-Glu-Ile-Glu Chemical Structure
  63. GC47771 NG 25 (hydrochloride hydrate) An inhibitor of MAP4K2 and TAK1 NG 25 (hydrochloride hydrate) Chemical Structure
  64. GC14332 NVP-BHG712 EphB4 inhibitor,potent and selective NVP-BHG712 Chemical Structure
  65. GA23328 Osteogenic Growth Peptide (10-14)

    OGP(10-14); Historphin

     YGFGG, C-terminal pentapeptide fragment of the osteogenic growth peptide (OGP), (H-8640), showed the full spectrum of OGP-like bioactivities. It has attracted considerable interest as bone anabolic agent and hematopoietic stimulator. Osteogenic Growth Peptide (10-14) Chemical Structure
  66. GC44583 PD 089828

    EGF/FGF/PDGF Receptor Tyrosine Kinase Inhibitor

     PD 089828 is a competitive inhibitor of the receptor tyrosine kinases FGFR1, PDGFRβ, and EGFR (IC50s = 0.15, 1.76, and 5.47 μM, respectively) and a noncompetitive inhibitor of the nonreceptor tyrosine kinase c-Src (IC50 = 0.18 μM). PD 089828 Chemical Structure
  67. GC72924 PD173952 PD173952 is a tyrosine kinases inhibitor with IC50s of 0.3, 1.7 and 6.6 nM against Lyn, Abl and Csk, respectively. PD173952 Chemical Structure
  68. GC13592 PD173955 Dual Src/Abl kinase inhibitor, ATP-competitive, PD173955 Chemical Structure
  69. GC17473 Pelitinib (EKB-569)

    EKB569

     Pelitinib (EKB-569) (EKB-569;WAY-EKB 569) is an irreversible inhibitor of EGFR with an IC50 of 38.5 nM; also slightly inhibits Src, MEK/ERK and ErbB2 with IC50s of 282, 800, and 1255 nM, respectively. Pelitinib (EKB-569) Chemical Structure
  70. GC14396 Ponatinib (AP24534)

    AP 24534

     Ponatinib (AP24534) (AP24534) is an orally active multi-targeted kinase inhibitor with IC50s of 0.37 nM, 1.1 nM, 1.5 nM, 2.2 nM, and 5.4 nM for Abl, PDGFRα, VEGFR2, FGFR1, and Src, respectively. Ponatinib (AP24534) Chemical Structure
  71. GC45828 Ponatinib-d8 An internal standard for the quantification of ponatinib Ponatinib-d8 Chemical Structure
  72. GC17990 PP 1

    AGL 1872; EI 275

    Potent, selective Src family tyrosine kinase inhibitor

     PP 1 Chemical Structure
  73. GC10344 PP 2 (AG 1879)

    AGL 1879

     A selective inhibitor of Src tyrosine kinases PP 2 (AG 1879) Chemical Structure
  74. GC13797 PP 3

    NSC 1401

     Negative control for the Src kinase inhibitor PP 2 PP 3 Chemical Structure
  75. GC11003 PP121 Dual inhibitor of tyrosine and phosphoinositide kinases PP121 Chemical Structure
  76. GC32835 PP58 PP58 is a pyrido[2,3-d]pyrimidine-based compound that inhibits PDGFR, FGFR and Src family activities with nanomolar IC50 values. PP58 Chemical Structure
  77. GC17137 pp60 c-src (521-533) (phosphorylated) Peptide corresponding to the pp60c-src carboxy terminal regulatory domain pp60 c-src (521-533) (phosphorylated) Chemical Structure
  78. GC73424 PRT062607 acetate

    P505-15 acetate; PRT-2607 acetate; BIIB-057 acetate

     PRT062607 (P505-15) acetate is an orally available Syk inhibitor (IC50: 1 nM) that inhibits inflammation and induction Apoptosis. PRT062607 acetate Chemical Structure
  79. GC31701 RK-24466 (KIN 001-51)

    Lymphocyte-specific Protein Tyrosine Kinase, RK-24466

     RK-24466 (KIN 001-51) (KIN 001-51) is a potent and selective Lck inhibitor; inhibits Lck (64-509) and LckCD isoforms with IC50s of less than 1 and 2 nM, respectively. RK-24466 (KIN 001-51) Chemical Structure
  80. GC15197 Saracatinib (AZD0530)

    AZD 0530

     Saracatinib (AZD0530) (AZD0530) is a potent Src family inhibitor with IC50s of 2.7 to 11 nM for c-Src, Lck, c-YES, Lyn, Fyn, Fgr, and Blk. Saracatinib (AZD0530) shows high selectivity over other tyrosine kinases. Saracatinib (AZD0530) Chemical Structure
  81. GN10633 Scutellarein

    6-Hydroxyapigenin

     Scutellarein Chemical Structure
  82. GC37620 Secretin, canine Secretin, canine is an endocrine hormone that stimulates the secretion of bicarbonate-rich pancreatic fluids. Secretin, canine Chemical Structure
  83. GC62675 SM1-71 SM1-71 (compound 5) is a potent TAK1 inhibitor, with a Ki of 160 nM, it also can covalently inhibit MKNK2, MAP2K1/2/3/4/6/7, GAK, AAK1, BMP2K, MAP3K7, MAPKAPK5, GSK3A/B, MAPK1/3, SRC, YES1, FGFR1, ZAK (MLTK), MAP3K1, LIMK1 and RSK2. SM1-71 can inhibit proliferation of multiple cancer cell lines. SM1-71 Chemical Structure
  84. GC50430 Squarunkin A hydrochloride UNC119 chaperone-cargo interaction inhibitor; disrupts Src activation Squarunkin A hydrochloride Chemical Structure
  85. GC16957 Src I1 Src I1 is a potent, ATP-competitive and selective dual site Src tyrosine kinase inhibitor with IC50 values of 44 nM for Src and 88nM for Lck. Src I1 Chemical Structure
  86. GC17500 SU6656 Src tyrosine kinases inhibitor SU6656 Chemical Structure
  87. GC44977 Syk Inhibitor

    OXSI 2, Spleen Tyrosine Kinase

     Syk Inhibitor is a bioavailable, cell-permeable Syk inhibitor with an EC50 of 313 nM and an IC50 of 14 nM. Syk Inhibitor Chemical Structure
  88. GC33168 T338C Src-IN-1 T338C Src-IN-1 is a potent mutant-Src T338C inhibitor; exhibited the most potent inhibition of T338C(IC50=111 nM) relative to WT c-Src (10-fold increase). T338C Src-IN-1 Chemical Structure
  89. GC33181 T338C Src-IN-2

    T338C Src-IN-2 is a potent mutant c-Src T338C kinase inhibitor with IC50 of 317 nM; also inhibits T338C/V323A and T338C/V323S with IC50 of 57 nM/19 nM.

     T338C Src-IN-2 Chemical Structure
  90. GC37771 TG 100572 TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100572 Chemical Structure
  91. GC37772 TG 100572 Hydrochloride TG 100572 Hydrochloride is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 nM for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100572 Hydrochloride Chemical Structure
  92. GC11622 TG 100801 TG 100801 Chemical Structure
  93. GC37773 TG 100801 Hydrochloride TG 100801 Hydrochloride is a prodrug that generates TG 100572 by de-esterification in development to treat age-related macular degeneration. TG 100572 is a multi-targeted kinase inhibitor which inhibits receptor tyrosine kinases and Src kinases; has IC50s of 2, 7, 2, 16, 13, 5, 0.5, 6, 0.1, 0.4, 1, 0.2 for VEGFR1, VEGFR2, FGFR1, FGFR2, PDGFRβ, Fgr, Fyn, Hck, Lck, Lyn, Src, Yes, respectively. TG 100801 Hydrochloride Chemical Structure
  94. GC34109 Tirbanibulin Mesylate (KX2-391 (Mesylate))

    KX2-391 Mesylate; KX01 Mesylate

     Tirbanibulin Mesylate (KX2-391 (Mesylate)) (KX2-391 Mesylate) is an inhibitor of Src that targets the peptide substrate site of Src, with GI50 of 9-60 nM in cancer cell lines. Tirbanibulin Mesylate (KX2-391 (Mesylate)) Chemical Structure
  95. GC38864 TL02-59 TL02-59 is an orally active, selective Src-family kinase Fgr inhibitor with an IC50 of 0.03 nM. TL02-59 inhibits Lyn and Hck with IC50s of 0.1 nM and 160 nM, respectively. TL02-59 potently suppresses acute myelogenous leukemia (AML) cell growth. TL02-59 Chemical Structure
  96. GC26001 TPX-0046 TPX-0046 Chemical Structure
  97. GC19366 UM-164

    DAS-DFGO-II

     UM-164 is a highly potent inhibitor of c-Src with a Kd of 2.7 nM. UM-164 Chemical Structure
  98. GC34110 WEHI-345 analog WEHI-345 analog is the analog of WEHI-345. WEHI-345 analog Chemical Structure
  99. GC13600 WH-4-023

    Dual LCK/SRC inhibitor

     Lck/Src inhibitor,potent and selective WH-4-023 Chemical Structure
  100. GC13102 XL228 A tyrosine kinase inhibitor XL228 Chemical Structure
  101. GC64992 YH-306 YH-306 is an antitumor agent. YH-306 suppresses colorectal tumour growth and metastasis via FAK pathway. YH-306 significantly inhibits the migration and invasion of colorectal cancer cells. YH-306 potently suppresses uninhibited proliferation and induces cell apoptosis. YH-306 suppresses the activation of FAK, c-Src, paxillin, and PI3K, Rac1 and the expression of MMP2 and MMP9. YH-306 also inhibita actin-related protein (Arp2/3) complex-mediated actin polymerization. YH-306 Chemical Structure

Items 1 to 100 of 101 total

per page
  1. 1
  2. 2

Set Descending Direction